These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 26416565

  • 1. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
    Lopus M, Smiyun G, Miller H, Oroudjev E, Wilson L, Jordan MA.
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1013-24. PubMed ID: 26416565
    [Abstract] [Full Text] [Related]

  • 2. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G, Azarenko O, Miller H, Rifkind A, LaPointe NE, Wilson L, Jordan MA.
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [Abstract] [Full Text] [Related]

  • 3. Effects of eribulin on microtubule binding and dynamic instability are strengthened in the absence of the βIII tubulin isotype.
    Wilson L, Lopus M, Miller HP, Azarenko O, Riffle S, Smith JA, Jordan MA.
    Biochemistry; 2015 Oct 27; 54(42):6482-9. PubMed ID: 26435331
    [Abstract] [Full Text] [Related]

  • 4. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.
    Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M.
    Mol Cancer Ther; 2010 May 27; 9(5):1339-48. PubMed ID: 20442307
    [Abstract] [Full Text] [Related]

  • 5. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R.
    Cancer Chemother Pharmacol; 2009 Jan 27; 63(2):201-12. PubMed ID: 18350296
    [Abstract] [Full Text] [Related]

  • 6. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability.
    Kamath K, Wilson L, Cabral F, Jordan MA.
    J Biol Chem; 2005 Apr 01; 280(13):12902-7. PubMed ID: 15695826
    [Abstract] [Full Text] [Related]

  • 7. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G.
    Cancer Chemother Pharmacol; 2008 Dec 01; 63(1):157-66. PubMed ID: 18347795
    [Abstract] [Full Text] [Related]

  • 8. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
    Kamath K, Jordan MA.
    Cancer Res; 2003 Sep 15; 63(18):6026-31. PubMed ID: 14522931
    [Abstract] [Full Text] [Related]

  • 9. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
    Wang W, Zhang H, Wang X, Patterson J, Winter P, Graham K, Ghosh S, Lee JC, Katsetos CD, Mackey JR, Tuszynski JA, Wong GK, Ludueña RF.
    Protoplasma; 2017 May 15; 254(3):1163-1173. PubMed ID: 27943021
    [Abstract] [Full Text] [Related]

  • 10. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
    Dumontet C, Jordan MA, Lee FF.
    Mol Cancer Ther; 2009 Jan 15; 8(1):17-25. PubMed ID: 19139109
    [Abstract] [Full Text] [Related]

  • 11. Preclinical investigations with epothilones in breast cancer models.
    Burris HA.
    Semin Oncol; 2008 Apr 15; 35(2 Suppl 2):S15-21; quiz S39. PubMed ID: 18410795
    [Abstract] [Full Text] [Related]

  • 12. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD.
    Future Oncol; 2008 Aug 15; 4(4):483-500. PubMed ID: 18684060
    [Abstract] [Full Text] [Related]

  • 13. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA.
    Clin Breast Cancer; 2008 Dec 15; 8(6):487-92. PubMed ID: 19073502
    [Abstract] [Full Text] [Related]

  • 14. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF, Lee FY, Canetta RM.
    Anticancer Drugs; 2014 May 15; 25(5):599-609. PubMed ID: 24398663
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of ixabepilone, a novel epothilone analogue.
    Pivot X, Dufresne A, Villanueva C.
    Clin Breast Cancer; 2007 Apr 15; 7(7):543-9. PubMed ID: 17509162
    [Abstract] [Full Text] [Related]

  • 16. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L.
    Oncologist; 2008 Mar 15; 13(3):214-21. PubMed ID: 18378531
    [Abstract] [Full Text] [Related]

  • 17. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
    Kanakkanthara A, Northcote PT, Miller JH.
    Mol Cancer Ther; 2012 Feb 15; 11(2):393-404. PubMed ID: 22180309
    [Abstract] [Full Text] [Related]

  • 18. CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
    Pabla N, Sparreboom A.
    Clin Cancer Res; 2015 Mar 15; 21(6):1237-9. PubMed ID: 25770292
    [Abstract] [Full Text] [Related]

  • 19. Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships.
    Altmann KH, Memmert K.
    Prog Drug Res; 2008 Mar 15; 66():273, 275-334. PubMed ID: 18416309
    [Abstract] [Full Text] [Related]

  • 20. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
    Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW, Kavallaris M.
    J Natl Cancer Inst; 2006 Oct 04; 98(19):1363-74. PubMed ID: 17018783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.